First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck (Companion Faculty Lecture)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck (Companion Faculty Lecture)
-
Narrated by:
-
By:
Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics:
- Overview of small cell lung cancer (SCLC) (0:00)
- First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50)
- Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36)
- Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide followed by maintenance lurbinectedin/atezolizumab (18:46)
- Case: A woman in her mid 70s with ES-SCLC experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (21:21)
CME information and select publications
adbl_web_anon_alc_button_suppression_t1
No reviews yet